|
1
|
Tao Z, Shi A, Lu C, Song T, Zhang Z and
Zhao J: Breast cancer: epidemiology and etiology. Cell Biochem
Biophys. 72:333–338. 2014. View Article : Google Scholar
|
|
2
|
Lester SC and Hicks DG: Diagnostic
Pathology: Breast. 2nd. Elsevier Health Sciences; 2016
|
|
3
|
Lyman GH, Temin S, Edge BS, Newman LA,
Turner RR, Weaver DL, Benson AB III, Bosserman LD, Burstein HJ,
Cody H III, et al: Sentinel lymph node biopsy for patients with
early-stage breast cancer: American Society of Clinical Oncology
clinical practice guideline update. J Clin Oncol. 32:1365–1383.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weigelt B, Hu Z, He X, Livasy C, Carey LA,
Ewend MG, Glas AM, Perou CM and Van't Veer LJ: Molecular portraits
and 70-gene prognosis signature are preserved throughout the
metastatic process of breast cancer. Cancer Res. 65:9155–9158.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weigelt B, Peterse JL and van 't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jones TI, Neboori H, Wu H, Yang Q, Haffty
BG, Evans S, Higgins S and Moran MS: Are breast cancer subtypes
prognostic for nodal involvement and associated with
clinicopathologic features at presentation in early-stage breast
cancer? Ann Surg Oncol. 20:2866–2872. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Byler S, Goldgar S, Heerboth S, Leary M,
Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects
of breast cancer progression and therapy. Anticancer Res.
34:1071–1077. 2014.PubMed/NCBI
|
|
8
|
Weigel MT and Dowsett M: Current and
emerging biomarkers in breast cancer: Prognosis and prediction.
Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Boer M, van Dijck JA, Bult P, Borm GF
and Tjan-Heijnen VC: Breast cancer prognosis and occult lymph node
metastases, isolated tumor cells, and micrometastases. J Natl
Cancer Inst. 102:410–425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harlow SP and Weaver DL: Diagnosis,
staging and the role of sentinel lymph node biopsy in the nodal
evaluation of breast cancer. http://www.uptodate.com/contents/overview-of-sentinel-lymph-node-biopsy-in-breast-cancerDecember
12–2016
|
|
12
|
Veta M, Pluim JP, Van Diest PJ and
Viergever MA: Breast cancer histopathology image analysis: A
review. IEEE Trans Biomed Eng. 61:1400–1411. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Karakatsanis A, Christiansen PM, Fischer
L, Hedin C, Pistioli L, Sund M, Rasmussen NR, Jørnsgård H,
Tegnelius D, Eriksson S, et al: The Nordic SentiMag trial: A
comparison of super paramagnetic iron oxide (SPIO) nanoparticles
versus Tc(99) and patent blue in the detection of sentinel node
(SN) in patients with breast cancer and a meta-analysis of earlier
studies. Breast Cancer Res Treat. 157:281–294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Upender S, Mohan H, Hand U and Attri AK:
Intraoperative evaluation of sentinel lymph nodes in breast
carcinoma by imprint cytology, frozen section and rapid
immunohistochemistry. Diagn Cytopathol. 37:871–875. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soares EW, Nagai HM, Bredt LC, da Cunha AD
Jr, Andrade RJ and Soares GV: Morbidity after conventional
dissection of axillary lymph nodes in breast cancer patients. World
J Surg Oncol. 12:672014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Z, Wu LC and Chen JQ: Sentinel lymph
node biopsy compared with axillary lymph node dissection in early
breast cancer: A meta-analysis. Breast Cancer Res Treat.
129:675–689. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gipponi M, Fregatti P, Garlaschi A,
Murelli F, Margarino C, Depaoli F, Baccini P, Gallo M and Friedman
D: Axillary ultrasound and Fine-Needle Aspiration Cytology in the
preoperative staging of axillary node metastasis in breast cancer
patients. Breast. 30:146–150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Co M and Kwong A: Preoperative Sentinel
Node Mapping in Sentinel Node Biopsy in Early Breast Cancers-Is It
Cost-Effective? Clin Breast Cancer. 2016.(Epub ahead of print).
PubMed/NCBI
|
|
19
|
Chirappapha P, Lohsiriwat V, Kongdan Y,
Lertsithichai P, Sukarayothin T, Supsamutchai C, Talakhadze N and
Zurrida S: Sentinel lymph node biopsy under local anesthesia in
patients with breast cancer. Gland Surg. 1:151–155. 2012.PubMed/NCBI
|
|
20
|
Luini A, Gatti G, Frasson A, Naninato P,
Magalotti C, Arnone P, Viale G, Pruneri G, Galimberti V, De Cicco C
and Veronesi U: Sentinel lymph node biopsy performed with local
anesthesia in patients with early-stage breast carcinoma. Arch
Surg. 137:1157–1160. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leidenius MH, Vironen JH, Heikkilä PS and
Joensuu H: Influence of isolated tumor cells in sentinel nodes on
outcome in small, node-negative (pT1N0M0) breast cancer. Ann Surg
Oncol. 17:254–262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gobardhan PD, Elias SG, Madsen EV, Bongers
V, Ruitenberg HJ, Perre CI and Van Dalen T: Prognostic value of
micrometastases in sentinel lymph nodes of patients with breast
carcinoma: A cohort study. Ann Oncol. 20:41–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cul'bová M, Lasabová Z, Stanclová A,
Tilandyová P, Zúbor P, Fiolka R, Danko J and Visnovský J:
Methylation of selected tumor-supressor genes in benign and
malignant ovarian tumors. Ceska Gynekol. 76:274–279.
2011.PubMed/NCBI
|
|
24
|
Fiolka R, Zubor P, Janusicova V, Visnovsky
J, Mendelova A, Kajo K, Lasabova Z, Plank L and Danko J: Promoter
hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and
CDH1 in endometrial cancer. Oncol Rep. 30:2878–2886.
2013.PubMed/NCBI
|
|
25
|
Alvarez C, Tapia T, Cornejo V, Fernandez
W, Muñoz A, Camus M, Alvarez M, Devoto L and Carvallo P: Silencing
of tumor suppressor genes RASSF1A, SLIT2 and WIF1 by promoter
hypermethylation in hereditary breast cancer. Mol Carcinog.
52:475–487. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rauscher GH, Kresovich JK, Poulin M, Yan
L, Macias V, Mahmoud AM, Al-Alem U, Kajdacsy-Balla A, Wiley EL,
Tonetti D and Ehrlich M: Exploring DNA methylation changes in
promoter, intragenic, and intergenic regions as early and late
events in breast cancer formation. BMC Cancer. 15:8162015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO Classification of Tumours of the Breast.
4th. Lyon: IARC; 2012
|
|
28
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Elston C.W..Ellis I. O.: Histopathology.
1991.19:403–410. Histopatology. 41:151–153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hammond ME, Haves DF, Wolff AC, Mangu PB
and Temin S: American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Oncol Pract. 6:195–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang KT, Mikeska T, Li J, Takano EA,
Millar EK, Graham PH, Boyle SE, Campbell IG, Speed TP, Dobrovic A
and Fox SB: Assessment of DNA methylation profiling and copy number
variation as indications of clonal relationship in ipsilateral and
contralateral breast cancers to distinguish recurrent breast cancer
from a second primary tumour. BMC Cancer. 15:6692015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wojdacz TK and Dobrovic A:
Methylation-sensitive high resolution melting (MS-HRM): A new
approach for sensitive and high-throughput assessment of
methylation. Nucleic Acids Res. 35:e412007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
R Core Team. R, . A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: https://www.R-project.org/2015
|
|
36
|
Dammann R, Schagdarsurengin U, Seidel C,
Strunnikova M, Rastetter M, Baier K and Pfeifer GP: The tumor
suppressor RASSF1A in human carcinogenesis: An update. Histol
Histopathol. 20:645–663. 2005.PubMed/NCBI
|
|
37
|
Agathanggelou A, Honorio S, Macartney DP,
Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R,
Shaw JA, et al: Methylation associated inactivation of RASSF1A from
region 3p21. 3 in lung, breast and ovarian tumours. Oncogene.
20:1509–1518. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Agathanggelou A, Cooper WN and Latif F:
Role of the Ras-association domain family 1 tumor suppressor gene
in human cancers. Cancer Res. 65:3497–3508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dammann R, Yang G and Pfeifer GP:
Hypermethylation of the cpG island of Ras association domain family
1A (RASSF1A), a putative tumor suppressor gene from the 3p21. 3
locus, occurs in a large percentage of human breast cancers. Cancer
Res. 61:3105–3109. 2001.PubMed/NCBI
|
|
40
|
Ghazaleh HA, Chow RS, Choo SL, Pham D,
Olesen JD, Wong RX, Onyskiw C and Baksh S: 14-3-3 mediated
regulation of the tumor suppressor protein, RASSF1A. Apoptosis.
15:117–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shivakumar L, Minna J, Sakamaki T, Pestell
R and White MA: The RASSF1A tumor suppressor blocks cell cycle
progression and inhibits cyclin D1 accumulation. Mol Cell Biol.
22:4309–4318. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dallol A, Agathanggelou A, Fenton SL,
Ahmed-Choudhury J, Hesson L, Vos MD, Clark GJ, Downward J, Maher ER
and Latif F: RASSF1A interacts with microtubule-associated proteins
and modulates microtubule dynamics. Cancer Res. 64:4112–4116. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Duffy MJ, Sturgeon CM, Sölétormos G, Barak
V, Molina R, Hayes DF, Diamandis EP and Bossuyt PM: Validation of
new cancer biomarkers: A position statement from the European group
on tumor markers. Clin Chem. 61:809–820. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lewis CM, Cler LR, Bu DW, Zöchbauer-Müller
S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD and Euhus DM:
Promoter hypermethylation in benign breast epithelium in relation
to predicted breast cancer risk. Clin Cancer Res. 11:166–172.
2005.PubMed/NCBI
|
|
45
|
Müller HM, Widschwendter A, Fiegl H,
Ivarsson L, Goebel G, Perkmann E, Marth C and Widschwendter M: DNA
methylation in serum of breast cancer patients: An independent
prognostic marker. Cancer Res. 63:7641–7645. 2003.PubMed/NCBI
|
|
46
|
Marino AL, Evangelista AF, Vieira RA,
Macedo T, Kerr LM, Abrahão-Machado LF, Longatto-Filho A, Silveira
HC and Marques MM: MicroRNA expression as risk biomarker of breast
cancer metastasis: A pilot retrospective case-cohort study. BMC
Cancer. 14:7392014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sequeiros T, García M, Montes M, Oliván M,
Rigau M, Colás E, De Torres I, Morote J, Reventós J and Doll A:
Molecular markers for prostate cancer in formalin-fixed
paraffin-embedded tissues. Biomed Res Int. 2013:2836352013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
van Hoesel AQ, Sato Y, Elashoff DA, Turner
RR, Giuliano AE, Shamonki JM, Kuppen PJ, van de Velde CJ and Hoon
DS: Assessment of DNA methylation status in early stages of breast
cancer development. Br J Cancer. 108:2033–2038. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Schrijver WA, Jiwa LS, van Diest PJ and
Moelans CB: Promoter hypermethylation profiling of distant breast
cancer metastases. Breast Cancer Res Treat. 151:41–55. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Fackler MJ, McVeigh M, Evron E, Garrett E,
Mehrotra J, Polyak K, Sukumar S and Argani P: DNA methylation of
RASSF1A, HIN-1, RAR-β, Cyclin D2 and Twist in in situ and invasive
lobular breast carcinoma. Int J Cancer. 107:970–975. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fackler MJ, McVeigh M, Mehrotra J, Blum
MA, Lange J, Lapides A, Garrett E, Argani P and Sukumar S:
Quantitative multiplex methylation-specific PCR assay for the
detection of promoter hypermethylation in multiple genes in breast
cancer. Cancer Res. 64:4442–4452. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Swift-Scanlan T, Vang R, Blackford A,
Fackler MJ and Sukumar S: Methylated genes in breast cancer:
Associations with clinical and histopathological features in a
familial breast cancer cohort. Cancer Biol Ther. 11:853–865. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Feng W, Orlandi R, Zhao N, Carcangiu ML,
Tagliabue E, Xu J, Bast RC Jr and Yu Y: Tumor suppressor genes are
frequently methylated in lymph node metastases of breast cancers.
BMC Cancer. 10:3782010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rouzier R, Extra JM, Klijanienko J, Falcou
MC, Asselain B, Vincent-Salomon A, Vielh P and Bourstyn E:
Incidence and prognostic significance of complete axillary
downstaging after primary chemotherapy in breast cancer patients
with T1 to T3 tumors and cytologically proven axillary metastatic
lymph nodes. J Clin Oncol. 20:1304–1310. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fisher ER, Anderson S, Redmond C and
Fisher B: Pathologic findings from the national surgical adjuvant
breast project protocol B-06: 10-year pathologic and clinical
prognostic discriminants. Cancer. 71:2507–2514. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fitzgibbons PL, Page DL, Weaver D, Thor
AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly
JL, et al: Prognostic factors in breast cancer: College of American
Pathologists consensus statement 1999. Arch Pathol Lab Med.
124:966–978. 2000.PubMed/NCBI
|
|
57
|
Jatoi I, Hilsenbeck SG, Clark GM and
Osborne CK: Significance of axillary lymph node metastasis in
primary breast cancer. J Clin Oncol. 17:2334–2340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Weiss M, Meyer M, Siegert S, Bartenstein P
and Pfluger T: Metastases in patients with breast cancer despite of
negative sentinel lymph node. Has the concept to be changed?
Nuklearmedizin. 52:14–20. 2013.PubMed/NCBI
|
|
59
|
Wen HY, Krystel-Whittemore M, Patil S,
Pareja F, Bowser ZL, Dickler MN, Norton L, Morrow M, Hudis CA and
Brogi E: Breast carcinoma with an Oncotype Dx recurrence score<
18: Rate of distant metastases in a large series with clinical
follow-up. Cancer. 123:131–137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wojdacz TK, Møller TH, Thestrup BB,
Kristensen LS and Hansen LL: Limitations and advantages of MS-HRM
and bisulfite sequencing for single locus methylation studies.
Expert Rev Mol Diagn. 10:575–580. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wojdacz TK, Windeløv JA, Thestrup BB,
Damsgaard TE, Overgaard J and Hansen L: Identification and
characterization of locus-specific methylation patterns within
novel loci undergoing hypermethylation during breast cancer
pathogenesis. Breast Cancer Res. 16:R172014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Dobrovic A: Analysis of DNA methylation in
clinical samples: Methods and applicationsmolecular pathology in
cancer research. pp. 261–277. Springer; New York: 2016, View Article : Google Scholar
|
|
63
|
Galimberti V, Cole BF, Zurrida S, Viale G,
Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, et
al: Axillary dissection versus no axillary dissection in patients
with sentinel-node micrometastases (IBCSG 23-01): A phase 3
randomised controlled trial. Lancet Oncol. 14:297–305. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Giuliano AE, Ballman K, McCall L, Beitsch
P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M and
Hunt KK: Locoregional Recurrence After Sentinel Lymph Node
Dissection With or Without Axillary Dissection in Patients With
Sentinel Lymph Node Metastases: Long-term Follow-up From the
American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011
Randomized Trial. Ann Surg. 264:413–420. 2016. View Article : Google Scholar : PubMed/NCBI
|
